Body mass index in girls with idiopathic central precocious puberty during and after treatment with GnRH analogues. (December 2016)

• Record Type: Journal Article
• Authors: Arcari, A. J.; Gryngarten, M. G.; Freire, A. V.; Ballerini, M.; Ropelato, M.; Bergadá, I.; Escobar, M.
• Is Part Of: International journal of pediatric endocrinology. Volume 2016(2016)
• Page Start: 1
• Page End: 7
• Publication Date: 2016-12
• Subjects: Central Precocious Puberty -- BMI -- GnRH analogues; Pediatric endocrinology -- Periodicals; Endocrine glands -- Diseases -- Periodicals; 618.924
• DOI: 10.1186/s13633-016-0033-7
• Languages: English
• ISSNs: 1687-9856

Abstract

Abstract Background In girls with Idiopathic Central Precocious Puberty (ICPP) concern has been raised by the potential impact of GnRH-analogues (GnRHa) treatment on body weight. We evaluated the effect of GnRHa on Body Mass Index (BMI) in girls with ICPP according to weight status at diagnosis. Methods One hundred seventeen ICPP girls were divided according to pretreatment weight status in: normal weight (NW), overweight (OW) and obese (OB). BMI at one and two years of treatment was assessed. BMI-SDS of 60 patients who reached adult height (AH) was compared to that of 33 ICPP untreated girls. Results NW girls significantly increased their baseline BMI-SDS at 1 and 2 years of treatment. OW girls only had a significant increment at one year of treatment while OB girls showed no BMI-SDS change. Patients evaluated at AH (at least four years after GnRHa withdrawal) showed a significant decrease on BMI compared to baseline and a significantly lower BMI than the untreated group. Conclusion In ICPP girls the BMI increase under GnRHa was inversely related to the pretreatment weight status. In the long term follow-up, no detrimental effect of GnRHa on body weight was observed. BMI-SDS was lower in treated than in untreated girls.